Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 65 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PiB Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Imaging Studies in Corticobasal Syndrome

NCT07000851
View directory record Official record
Conditions
Cortico Basal Degeneration, Corticobasal Syndrome, Corticobasal Syndrome(CBS), Corticobasal Degeneration, Corticobasal Degeneration (CBD), Corticobasal Syndrome (CBS)
Interventions
C-11 ER176 Radiotracer, C-11 PiB, AV1451 Tau
Diagnostic Test
Lead sponsor
Jennifer Whitwell
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

NCT01723553
View directory record Official record
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1Phase 2 Interventional

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

NCT04596475
View directory record Official record
Conditions
Hepatitis C, Hepatitis C Virus Infection, Response to Therapy of
Interventions
glecaprevir/pibrentasvir (GLE/PIB)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 24, 2026, 2:49 AM EDT
Enrolling by invitation No phase listed Observational

Clinico-Pathologic-Genetic-Imaging Study of Neurodegenerative and Related Disorders

NCT04680130
View directory record Official record
Conditions
PSP, CBD, PCA, LPA, Semantic Dementia, Semantic Aphasia, Behavioral Variant of Frontotemporal Dementia, FTD, PPA, Apraxia of Speech, MSA - Multiple System Atrophy, Parkinson Disease
Interventions
C-11 PiB, AV1451 Tau, C-11 ER176
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 24, 2026, 2:49 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

NCT05731440
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Fluselenamyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

GSK3739937 First-Time-In-Human (FTIH) Study in Healthy Volunteers

NCT04493684
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3739937 (PIB), Placebo, GSK3739937 (Tablet)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 24, 2026, 2:49 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

NFL LONG Prospective Study

NCT04263337
View directory record Official record
Conditions
Concussion, Brain
Interventions
[11C] PiB, [18F] PBR111, [18F] Flortaucipir
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years to 70 Years · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
3
States / cities
Waltham, Massachusetts • Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Clinical Investigation of Eye C Better's Photobionic Intraocular Pressure Biomonitor Tonometer

NCT07762053
View directory record Official record
Conditions
Elevated Intraocular Pressure (IOP)
Interventions
Photobionic IOP Tonometer (PIB)
Device
Lead sponsor
EyeCBetter Corporation
Industry
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
La Quinta, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

NCT05393271
View directory record Official record
Conditions
HIV Infections
Interventions
VH4011499, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 24, 2026, 2:49 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

A Study of Imaging in Demyelinating Diseases

NCT05805839
View directory record Official record
Conditions
Multiple Sclerosis, Inflammatory Demyelinating Disease
Interventions
C-11 ER176 Radiotracer, C11 Pittsburgh Compound B, PET/CT scan, MRI
Drug · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Recruiting Early Phase 1 Interventional

Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

NCT06932809
View directory record Official record
Conditions
Tauopathies
Interventions
18F-JSS20-183A PET, Brain MRI, Amyloid PET, Neurological Assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 24, 2026, 2:49 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
11C-PiB
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study in Healthy Subjects

NCT00924911
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 24, 2026, 2:49 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

NCT06032026
View directory record Official record
Conditions
Tauopathies
Interventions
11C-HY-2-15 PET, brain MRI, Amyloid PET scan, Neurological assessments
Drug · Diagnostic Test · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 24, 2026, 2:49 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

NCT05361382
View directory record Official record
Conditions
Alzheimer Disease
Interventions
18F-Flortaucipir radiopharmaceutical, 18F-MK-6240 radiopharmaceutical, Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)
Drug
Lead sponsor
Tharick Pascoal
Other
Eligibility
18 Years to 90 Years
Enrollment
822 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
7
States / cities
Berkeley, California • San Francisco, California • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

NCT03212521
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 24, 2026, 2:49 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy

NCT03503331
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[C-11]PiB-PET/MRI
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

NCT03958630
View directory record Official record
Conditions
Dementia
Interventions
11C-ER176, 11C-PIB, Positron Emission Tomography (PET) Scan
Drug · Diagnostic Test
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1 Interventional

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

NCT03305471
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Florbetapir Calibration to the Centiloid Scale

NCT02120664
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Florbetapir (18F), 11C-PiB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 24, 2026, 2:49 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Implications of Amyloid Pathology

NCT00900770
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 29, 2009 · Synced Oct 24, 2026, 2:49 AM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Quantitative Imaging of Brain Glymphatic Function in Humans

NCT04768101
View directory record Official record
Conditions
Parkinson Disease
Interventions
[11C]-PIB
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
55 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Recruiting Phase 1 Interventional

Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07733674
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
203Pb-RMX-VHPIB injection, SPECT/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Radiomedix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 24, 2026, 2:49 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

NCT03067129
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir Adult Formulation, Glecaprevir + Pibrentasvir Pediatric Formulation
Drug
Lead sponsor
AbbVie
Industry
Eligibility
3 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
15
States / cities
San Francisco, California • Aurora, Colorado • Hartford, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 24, 2026, 2:49 AM EDT